NanoViricides, Inc. (OTC BB: NNVC.OB), reported today that the CBS affiliate TV station WBRZ interviewed Professor K. Gus Kousoulas , PhD, in which he explained the potential implications of the Company’s nanoviricides™ anti-Herpes drug candidates.
“Over 90% of the people are infected with Herpes, whether they know it or not,” said Dr. Kousoulas, adding “it can manifest as cold sores or genital herpes. [These manifestations] can be very painful, especially for women.” He also commented that “Unlike true love, herpes is forever,” referring to the fact that the herpes virus goes dormant in the body between recurrent manifestations, and that there is at present no cure for herpes.
“A nanoviricide drug could be an important breakthrough,” he said, explaining, “the duration of a cold sore could be reduced drastically, from a month to just a few days [by applying a nanoviricide skin cream],” based on studies conducted in the laboratories at the Louisiana State University’s (LSU) Division of Biotechnology and Molecular Medicine (BIOMMED). In cell culture testing, his laboratory found that certain nanoviricides eliminated 99.99% of the virus from infected cells.
A video excerpt of the interview can be found at 2theadvocate.com | News | Possible progress in herpes treatment — Baton Rouge, LA. The video was also linked to the front page of The Drudge Report, DRUDGE REPORT 2009®.
The LSU School of Veterinary Medicine has received a grant of $11.1M in July 2009, adding to a previous award of $9.9M in 2004, for the LSU Center of Biomedical Research Excellence (COBRE) from the National Institutes of Health (NIH). Konstantin G. Kousoulas, PhD, Professor of Veterinary Virology and Director of BIOMMED, is the administrator of the COBRE program at the LSU School of Veterinary Medicine. He is also the Mary Louise Martin Professor of Virology and the Director of LSU-Tulane Center for Experimental Infectious Disease Research.
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients